| Kudirat Folorunsho Sunmonu, NP-C | |
|
77 Sugar Creek Center Blvd Ste 600, Sugar Land, TX 77478-3688 | |
| (832) 474-2053 | |
| Not Available |
| Full Name | Kudirat Folorunsho Sunmonu |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 77 Sugar Creek Center Blvd Ste 600, Sugar Land, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548777915 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 786687 (Texas) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | AP134751 (Texas) | Primary |
| Entity Name | Update Family Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922735828 PECOS PAC ID: 6901288182 Enrollment ID: O20220804001340 |
News Archive
Arpida Ltd. has announced that it has received approval from the US Food and Drug Administration for a Phase II trial with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.
Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.
DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.
"Congress has an historic opportunity to join with the American College of Physicians (ACP), other physician organizations and employers to redesign Medicare payment policies to provide incentives for patient-centered care," ACP told the House Committee on Ways and Means Subcommittee on Health in a written statement.
​Diabetic patients could benefit from a breakthrough that enables scientists to take cells from the pancreas and change their function to produce insulin.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kudirat Folorunsho Sunmonu, NP-C 77 Sugar Creek Center Blvd Ste 600, Sugar Land, TX 77478-3688 Ph: (832) 474-2053 | Kudirat Folorunsho Sunmonu, NP-C 77 Sugar Creek Center Blvd Ste 600, Sugar Land, TX 77478-3688 Ph: (832) 474-2053 |
News Archive
Arpida Ltd. has announced that it has received approval from the US Food and Drug Administration for a Phase II trial with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.
Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.
DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.
"Congress has an historic opportunity to join with the American College of Physicians (ACP), other physician organizations and employers to redesign Medicare payment policies to provide incentives for patient-centered care," ACP told the House Committee on Ways and Means Subcommittee on Health in a written statement.
​Diabetic patients could benefit from a breakthrough that enables scientists to take cells from the pancreas and change their function to produce insulin.
› Verified 7 days ago